Management of non-small cell lung cancer with oligometastasis.

Abstract

Patients with oligometastatic Non-Small Cell Lung Cancer (NSCLC) present a potential opportunity for curative therapy; however, the challenge remains the definitive treatment of their localized disease and ablation of their limited overt metastatic sites of disease. In selecting patients with oligometastatic NSCLC for definitive therapy, proper staging through radiographic studies, including PET and brain MRI, and the pathologic staging of the mediastinal lymph nodes and potential sites of metastatic disease, are critical. With that in mind, the available literature suggests that in highly selected patients with solitary metastases to the brain, adrenals and other organs, long term survival may be achieved with combined definitive therapy of both the primary lung tumor and the solitary metastatic site.

• Authors: Liza C Villaruz, Gregory J Kubicek, Mark A Socinski
• Journal: Current oncology reports (Curr Oncol Rep) Vol. 14 Issue 4 Pg. 333-41 (Aug 2012) ISSN: 1534-6269 [Electronic] United States
• PMID: 22535505 (Publication Type: Journal Article, Review)

Topics

• Adrenal Gland Neoplasms (secondary, therapy)
• Brain Neoplasms (secondary, therapy)
• Carcinoma, Non-Small-Cell Lung (secondary, therapy)
• Humans
• Lung Neoplasms (pathology)